In a study of women with bone metastases from breast cancer, Xgeva™ (denosumab) delayed bone complications for five months longer than Zometa® (zoledronic acid). These updated results from a Phase III clinical trial were presented at the 2010 San Antonio Breast Cancer Symposium.
Metastatic cancer refers to cancer that has spread to distant sites in the body. Several types of cancer—including breast cancer—have a tendency to spread to the bone. Bone metastases can lead to serious problems such as fracture and spinal cord compression and may require treatment with surgery or radiation therapy.
Bisphosphonate drugs such as Zometa are commonly used to reduce the risk of complications from bone metastases. Researchers continue, however, to explore new approaches to treatment.
Xgeva is a drug that targets a protein known as the RANK ligand. This protein regulates the activity of osteoclasts (cells that break down bone). Xgeva was recently approved for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers.
To directly compare Xgeva to Zometa among breast cancer patients with bone metastases, researchers conducted a Phase III clinical trial among more than 2,000 patients. Study participants were assigned to receive either Xgeva or Zometa. Zometa is given intravenously, and Xgeva is given as a subcutaneous (under-the-skin) injection.
The objective of the study was to determine whether the occurrence of bone complications (“skeletal related events”) differed between the two study groups. The bone complications that were evaluated were fracture, radiation to the bone, surgery to the bone, and spinal cord compression.
The results of this study suggest that Xgeva is more effective than Zometa at delaying or preventing skeletal complications in breast cancer patients with bone metastases.
Reference: Stopeck A, Martin M, Ritchie D et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Presented at the 33rd annual San Antonio Breast Cancer Symposium, December 8-12, 2010. Abstract P6-14-01.
Copyright © 2016 CancerConsultants. All Rights Reserved.
[ how much is viagra from canada | female viagra 100mg pills $116.00 | abilify 20mg pills $102.00 | myambutol 600mg pills $141.00 | lotrisone cream in 7gr tube $132.00 | adhd mentat 60 tablets bottle $138.00 | aristocort 10mg pills $162.00 | coumadin 1mg pills $151.00 | alternative viagra drug | viagra 25mg pills $140.00 | arcoxia 120mg pills $146.00 | dipyridamole 75mg pills $216.00 | acticin topical 30gm tube $87.00 | order viagra air travel | altace 5mg pills $152.00 | minomycin 100mg pills $387.00 | methocarbamol 500mg pills $333.00 | zebeta 10mg pills $174.00 | buspirone 5mg $82.00 | dapsone 100mg pills $171.00 | cessation zyban 150mg pills $91.00 | advair diskus 500mcg inhaler $148.00 | detox acai berry 60 capsule bottle $122.00 | myambutol 1000mg pills $117.00 | zyprexa 15mg pills $345.00 | persantine 25mg pills $102.00 | floxin 200mg pills $140.00 | erythromycin 250mg pills $327.00 | paxil 30mg pills 360 pills $434.00 | ilosone 500mg pills $117.00 | canada generic viagra | sinequan 75mg pills $341.00 | viagra canadian pharmacy dosage | cialis 5mg pills $93.00 | gasex 100 tablet bottle $344.00 | viagra-aurochem 50mg $177.00 | risperdal 3mg pills $82.00 | macrobid 50mg pills $63.00 | aristocort 40mg pills $262.00 | clomipramine 50mg pills $124.00 | cialis canadian cost | buspar 5mg pills $82.00 | persantine 100mg pills $256.00 | maxalt 10mg pills $135.00 | history of viagra | allopurinol 300mg pills $90.00 | sublingual viagra pro 100mg pills $91.00 | detox liv.52 100 tablets bottle $118.00 | mirapex 1mg pills $174.00 | vigora 100mg pills $54.00 | nizoral 200mg pills $183.00 | seroquel 300mg pills $403.00 | xenical 120mg pills (brand) 84 $270.00 | benicar 40mg pills $251.00 ]
© Nebraska Hematology-Oncology | Web Design & Development by UNANIMOUS